survodutide mastery course
Unit 3 of 12

Dual Receptor Pharmacology

how survodutide signals through both GLP-1R and GCGR simultaneously

Two Receptors, One Molecule

Survodutide activates both the GLP-1 receptor and the glucagon receptor from a single peptide chain. This unit maps the downstream signaling cascades, explains why the receptor activation ratio between the two targets matters clinically, and connects structural features to receptor-level pharmacology.

Interactive Signaling Cascade

Trace the parallel signaling pathways activated by survodutide at each receptor.

receptor signaling cascade

key numbers

quick reference for survodutide's receptor pharmacology.

0.33 nM
GLP-1R EC50 (~4x less potent than native GLP-1)
0.52 nM
GCGR EC50 (~22x less potent than native glucagon)
1.6:1
GLP-1R to GCGR potency ratio
20-30%
caloric intake reduction via hypothalamic GLP-1R
EC50 values are from cell-based assays and do not directly predict clinical potency. In vivo, albumin binding, tissue distribution, and receptor density all modulate the effective concentration at each receptor. The 1.6:1 ratio is a design parameter, not a clinical outcome measure.

key terms

receptor pharmacology vocabulary for this unit. tap to expand.

G GLP-1R receptor
GLP-1 receptor. A class B GPCR expressed on pancreatic beta cells, hypothalamic neurons (POMC/AgRP), gastric smooth muscle, and cardiac tissue. Activation drives appetite suppression, glucose-dependent insulin secretion, and slowed gastric emptying.
G GCGR receptor
Glucagon receptor. A class B GPCR predominantly expressed on hepatocytes, with additional expression in kidney, adipose, and brain. Activation drives glycogenolysis, gluconeogenesis, beta-oxidation of fatty acids, and FGF21 secretion.
c cAMP second messenger
Cyclic adenosine monophosphate. The shared second messenger for both GLP-1R and GCGR signaling. Both receptors couple to Gs protein, activating adenylyl cyclase to elevate intracellular cAMP, which then activates PKA and Epac pathways.
E EC50 pharmacology
The concentration of drug that produces 50% of the maximum possible effect. A lower EC50 means higher potency. Survodutide's GLP-1R EC50 (0.33 nM) is lower than its GCGR EC50 (0.52 nM), meaning it is biased toward GLP-1R activation at low concentrations.
P POMC neurons neuroscience
Pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus. GLP-1R activation on these neurons signals satiety and suppresses hunger. The opposing NPY/AgRP neurons drive appetite and are inhibited by GLP-1R signaling.

dual receptor pharmacology -- the simple version

what it means for one molecule to talk to two different receptors at once.

Most drugs hit one target. Survodutide hits two: the GLP-1 receptor and the glucagon receptor. The GLP-1 receptor lives mainly in the brain and pancreas -- when survodutide activates it, you feel less hungry and your body releases more insulin to manage blood sugar. The glucagon receptor lives mainly in the liver -- when survodutide activates it, the liver starts burning its stored fat for energy and releases a helpful hormone called FGF21. Both receptors use the same internal alarm system (a molecule called cAMP), but because they sit on different organs, the downstream effects are completely different. Survodutide is slightly better at activating the GLP-1 receptor than the glucagon receptor, which keeps blood sugar under control while still getting the liver-fat-burning benefits.

A advanced: the shared Gs/cAMP signaling cascade term
Both GLP-1R and GCGR are class B GPCRs that couple to the same Gs protein. When survodutide binds either receptor, Gs activates adenylyl cyclase, which produces cyclic AMP (cAMP). cAMP then switches on protein kinase A (PKA) and Epac. The critical point is that PKA's downstream targets differ by cell type: in pancreatic beta cells it triggers insulin granule exocytosis, in hypothalamic POMC neurons it signals satiety, and in hepatocytes it upregulates CPT1a for fatty acid beta-oxidation. Same upstream cascade, entirely different physiological outcomes depending on which tissue the receptor sits in.
advanced: the 1.6:1 potency ratio and dose-dependent bias
Survodutide's EC50 at GLP-1R is 0.33 nM versus 0.52 nM at GCGR, producing a roughly 1.6:1 potency bias toward GLP-1R. At low doses, neither receptor is saturated and GLP-1R effects (appetite suppression, insulin secretion) predominate because the molecule reaches its half-maximal GLP-1R effect at a lower concentration. At higher doses both receptors approach saturation, and the absolute EC50 difference matters less -- glucagon-mediated hepatic effects become proportionally more prominent. This dose-dependent shift is clinically relevant: the Phase 2 MASH trial showed that 4.8 mg produced the best liver outcomes, while the 6.0 mg dose had more GI side effects from stronger receptor engagement.
advanced: cryo-EM and the two-domain binding mechanism
Cryo-electron microscopy structures of GCGR-Gs and GLP-1R-Gs complexes reveal that both receptors use a two-domain binding mechanism: the extracellular domain (ECD) captures the peptide's C-terminal region for initial docking, while the transmembrane domain (TMD) engages the N-terminal residues that trigger activation. Survodutide exploits this shared architecture -- its native glucagon backbone provides the C-terminal contacts that fit GCGR's ECD, while the engineered substitutions at positions 16, 18, 20, and 23 create additional contacts that satisfy GLP-1R's binding pocket. The binding pockets overlap but are not identical, allowing one peptide to productively engage both receptors without compromise.

two pathways, different targets

the GLP-1R and GCGR arms of survodutide activate the same upstream signaling cascade (Gs/cAMP/PKA) but diverge at the tissue level.

GLP-1R arm
hypothalamic appetite suppression (POMC activation, NPY/AgRP inhibition). pancreatic glucose-dependent insulin secretion. gastric emptying delay of 30-40%. potential cardioprotective anti-inflammatory effects.
GCGR arm
hepatic beta-oxidation via CPT1a upregulation (40-60% triglyceride reduction). FGF21 secretion as a metabolic hepatokine. bile acid synthesis via CYP7A1 upregulation. increased resting energy expenditure.

why the ratio matters

too much glucagon raises blood glucose. too little loses the hepatic benefit. zealand pharma tested multiple analogs to find the balance.

The GLP-1R/GCGR potency ratio is the central engineering constraint in survodutide's design. The molecule deliberately biases toward GLP-1R (EC50 0.33 nM) over GCGR (EC50 0.52 nM), producing a roughly 1.6:1 potency ratio. At lower doses, GLP-1R effects predominate -- appetite suppression and insulin secretion. At higher doses, both pathways approach saturation and glucagon-mediated hepatic effects become proportionally more prominent.

In the Phase 2 MASH trial, glycemic parameters improved despite the glucagon component, confirming that GLP-1-mediated insulin secretion successfully counterbalances GCGR-driven hepatic glucose output. This is the clinical validation of the ratio chosen during preclinical optimization.